Company Overview - Jade Biosciences is focused on developing best-in-class therapeutics for autoimmune diseases, having launched in mid-2024 with three key assets [2] - The company has licensed assets from Paragon Therapeutics, a Boston-based protein engineering company known for high-quality monoclonal antibodies and expertise in high-affinity binding antibodies and half-life extension technology [3] Strategic Focus - The strategy for the three assets involves targeting areas with high clinical validation while aiming to improve upon existing solutions [3]